I am disappointed that we are falling behind in the testing of women who have a genetic predisposition towards breast cancer. That is very important because there are obviously some families where there is a greater hereditary predisposition towards breast and ovarian cancers, which are caused by the same gene. Ovarian cancer is even more difficult to diagnose early and is more deadly. It is important, therefore, that the national genetic centre in Crumlin gets proper funding. The centre never seems to know what its budget is. Professor Peter Harper's report, which was produced by the centre last year and was sent to the Minister's Department, referred to the importance of a clinic and laboratory genetic service for hereditary breast and ovarian cancer and stressed the value of the four year pilot scheme which the Department has funded through the health research board. However, the centre has been funded ever since in jumps of €80,000, which is not much good. The Department accepted the Harper report so the value of it is known. A huge amount of money is not involved but programmes of this sort cannot be run on a stop-go basis because clinical scientists must be employed to do this research. We know the value of these genetic tests regarding the programming of treatment and we must make progress in this area.